This article was originally published in The Tan Sheet
FDA approves abbreviated new drug applications from Perrigo and Leiner Health Products' development partner, Dr. Reddy's Laboratories, for OTC versions of famotidine 20 mg acid indigestion treatment (Johnson & Johnson-Merck's Pepcid AC). The FDA approval on Sept. 25 for private label versions of the heartburn drug comes two days after Merck's exclusivity for the product expired. Both companies began shipping the product to retail outlets immediately following the approvals. Annual Pepcid AC sales total approximately $60 mil., according to Perrigo...
You may also be interested in...
Patent Case Ruling Allows For Launch Of Generic Pepcid Complete
The U.S. District Court for the Southern District of New York invalidated a key patent for Johnson & Johnson/Merck's Pepcid Complete, opening the door for Perrigo to enter the market with a private-label equivalent
LSI 2023: Intuitive Alums On Dawning Of Robotic Surgery To Digital OR Future
Robotic surgery pioneer and co-founder of Intuitive Surgical Frederic Moll joined Daniel Hawkins, Intuitive’s first non-technical hire, for a discussion on the evolution of surgical robotics and outlook for the future.
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.